Read More

Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)Worldwide rights come with $17

BDRX

Read More

FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV; Perinatal Guidelines Recognize Biktarvy As Alternative Regimen For Use During Pregnancy And For Those Trying To Conceive

– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV –– Perinatal Guidelines Recognize Biktarvy as Alternative

GILD

Read More

Tiziana Life Sciences Reports 3-Month Neuroimaging Scores In Multiple Sclerosis Patients Receiving Intranasal Foralumab; A Primary Endpoint With Clinical Measures Of EDSS (Disability) And MFIS (Fatigue) Is Currently Underway

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time,

TLSA